Search the Newsreel

Janus Henderson Group PLC Grows Stake in ANI Pharmaceuticals, Inc. $ANIP

Janus Henderson Group PLC significantly increased its stake in ANI Pharmaceuticals, Inc. during the first quarter of 2026, boosting its holdings by 1,308.1% to 109,552 shares valued at approximately $8.4 million. This move comes as ANI Pharmaceuticals reported strong quarterly earnings, beating analyst estimates …

ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect

ANI Pharmaceuticals (ANIP) to Release Quarterly Earnings on Friday

ANI Pharmaceuticals (ANIP) is scheduled to release its Q2 2026 earnings before market open on Friday, August 7th. Analysts project earnings of $2.01 per share and revenue of $260.13 million. The company surpassed analyst expectations in its previous quarter, reporting $2.05 EPS against an …

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI Pharmaceuticals (ANIP) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026. Despite a positive Earnings ESP, the stock's Zacks Rank #4 makes it difficult to definitively predict an earnings beat. Investors are advised to …

ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells 2,850 Shares of Stock

ANI Pharmaceuticals' (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the company's stock for $231,876, reducing his stake by 1.61%. Despite this insider sale, the company reported strong Q1 earnings, beating analyst expectations with 20.5% year-over-year revenue growth. Analysts maintain a "Moderate Buy" rating …

ANIP|ANI Pharmaceuticals Inc|Price:81.750|Chg%:+0.710

This article provides a detailed financial overview of ANI Pharmaceuticals Inc (ANIP), presenting its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, Revenue, Net Profit, and various margins, alongside projected earnings and revenue forecasts. The document …

ANI Pharmaceuticals (NASDAQ: ANIP) insider plans Form 144 sale of restricted shares

ANI Pharmaceuticals insider Stephen P. Carey has filed a Form 144 to sell 6,163 shares of common stock, valued at $499,449.52. These shares originate from Restricted Stock Awards granted on April 6, 2019, and the sale is planned for July 29, 2026, on NASDAQ. …

ANIP|ANI Pharmaceuticals Inc|Price:79.255|Chg%:-1.175

This article provides a comprehensive stock analysis of ANI Pharmaceuticals Inc (ANIP) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The analysis also covers institutional ownership, analyst ratings, and a detailed breakdown of how …

ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership significantly increased its stake in ANI Pharmaceuticals (ANIP) by 19.3% in the first quarter, now owning 2.52% of the company's shares. This comes as ANI Pharmaceuticals reported strong quarterly results, exceeding EPS and revenue consensus estimates, and provided positive fiscal …

ANI Pharmaceuticals Inc (ANIP) Institutional Confidence

ANI Pharmaceuticals Inc (ANIP) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 101.74%, showing a 1.25% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.87% of shares outstanding.

How Ani Pharmaceuticals Inc. (ANIP) Affects Rotational Strategy Timing

The article analyzes Ani Pharmaceuticals Inc. (ANIP) through quantitative research, highlighting a near-term neutral sentiment amidst mid and long-term weakness. It details specific trading strategies—Position, Momentum Breakout, and Risk Hedging—with defined entry points, targets, and stop losses. The analysis also provides multi-timeframe signal insights, …

ANI Pharmaceuticals Inc (ANIP) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of ANI Pharmaceuticals Inc (ANIP), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types by proportion and presents institutional shareholding trends over several quarters, including changes in the number of institutions …

BlackRock (ANIP) discloses 2.9M-share, 12.8% stake in ANI Pharmaceuticals

BlackRock, Inc. has filed an amended beneficial ownership report, disclosing a 12.8% stake in ANI Pharmaceuticals Inc. (ANIP). BlackRock's business units collectively beneficially own 2,899,843 shares of ANI Pharmaceuticals common stock, with sole voting power over 2,860,943 shares and sole dispositive power over all …

TradingKey

This article provides a comprehensive quarterly and annual income statement for ANI Pharmaceuticals Inc (ANIP) up to FY2026Q1, detailing key financial metrics such as total revenue, cost of revenue, operating expenses, and net income. It also includes an FAQ section explaining how to read …

ANI Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ANIP

This article provides a revenue breakdown for ANI Pharmaceuticals, Inc. (ANIP) for the last fiscal year. The company generated $883.37 million in revenue, with its Rare Disease and Brands segment contributing $483.93 million. The United States was the primary source of revenue, accounting for …

ANI Pharmaceuticals (NasdaqGM:ANIP) Stock Forecast & Analyst Predictions

ANI Pharmaceuticals is projected to grow earnings by 24% and revenue by 9.6% annually, with EPS growth of 13.8% and a forecasted 25.4% return on equity in three years. The company has frequently raised its revenue guidance for 2025 and 2026 and recently announced …

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Moderate Buy" from Analysts

ANI Pharmaceuticals (NASDAQ:ANIP) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $105.00. The company recently exceeded Q1 earnings expectations, reporting an EPS of $2.05 against an estimated $1.28, and revenue of $237.46 million, a 20.5% increase …

ANI Pharmaceuticals Inc (ANIP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of ANI Pharmaceuticals Inc (ANIP) stock information, focusing on its dividend and stock split history. It notes that no dividends have been distributed over the past five years and contains no data regarding historical stock splits. The page displays …

ANI Pharmaceuticals to report Q2 2026 earnings on August 7 with webcast discussion.

ANI Pharmaceuticals has announced it will release its second-quarter 2026 financial results on August 7, 2026, at 8:00 a.m. ET. Company executives will host a webcast and conference call to discuss the results, which will be accessible via their website. The company aims for …

Three ANI Pharmaceuticals executives will host Aug. 7 results call

ANI Pharmaceuticals (ANIP) will release its second-quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. President and CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz will host a webcast and conference call to discuss …

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced it will release its second-quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. A webcast and conference call will be hosted by CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease …

ANI Pharmaceuticals schedules webcast to discuss Q2 2026 results

ANI Pharmaceuticals announced it will release its second-quarter 2026 financial results on August 7, 2026, at 8:00 a.m. ET. A webcast and conference call will follow to discuss these results, accessible via the company's website. This news brief was generated by Public Technologies using …

Is ANI Pharmaceuticals (ANIP) A Bargain Following Its Positive SYNCHRONICITY Trial Results?

ANI Pharmaceuticals Inc (ANIP) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of ANI Pharmaceuticals Inc (ANIP), noting its current valuation score of 8.63, which ranks 87 out of 155 in the Pharmaceuticals industry. The company's current P/E ratio is 18.88, significantly below its recent high but above its recent …

ANIP5868601 Bond Profile — Key Metrics

This article provides key metrics for the ANIP5868601 bond issued by ANI Pharmaceuticals, Inc. It details the bond's issue and maturity dates, outstanding amount, face value, and coupon rate. The profile also includes a brief description of ANI Pharmaceuticals, Inc., highlighting its business segments …

ANI Pharmaceuticals (ANIP) GC has 2,466 shares withheld for taxes on RSU vesting

ANI Pharmaceuticals' Sr. VP, General Counsel & Secretary, Meredith Cook, had 2,466 shares of common stock withheld on July 18, 2026, to cover tax obligations related to the vesting of 4,820 restricted shares. The withholding price was $79.20 per share, and following this transaction, …

ANI Pharmaceuticals (ANIP) On Strong ILUVIEN Trial Data Is The Stock A Bargain

ANI Pharmaceuticals (ANIP) recently reported strong Phase 4 SYNCHRONICITY trial results for its ILUVIEN drug, showing improvements in visual acuity and retinal thickness for chronic non-infectious posterior segment uveitis. The stock trades at US$77.72, down 4.14% in the last 7 days, but it has …

How Positive SYNCHRONICITY Trial Data for ILUVIEN at ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story

ANI Pharmaceuticals recently reported positive topline results from its Phase 4 SYNCHRONICITY trial for ILUVIEN, supporting its expanded use in uveitis. This data reinforces ILUVIEN's role in the company's specialty asset strategy alongside Cortrophin Gel, contributing to a projected increase in revenue and earnings. …

ANI PHARMACEUTICALS INC : CANACCORD GENUITY INITIATES COVERAGE WITH HOLD RATING; TARGET PRICE $91

Canaccord Genuity has initiated coverage on ANI Pharmaceuticals Inc. with a "Hold" rating, setting a target price of $91. This announcement was made via Reuters on July 17, 2026. This article highlights the financial analyst's evaluation of the pharmaceutical company.

ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook

ANI Pharmaceuticals (ANIP) is experiencing significant growth driven by its Cortrophin Gel, which is anchoring the company's 2026 revenue targets. The company projects increased sales and profitability for 2026, supported by new commercial initiatives including a dedicated gout sales force and a prefilled syringe …

ANI Pharmaceuticals plans appeal after trial court ruling

ANI Pharmaceuticals (NASDAQ:ANIP) announced its intention to appeal a Delaware trial court's decision that denied its post-trial motions in a dispute with CG Oncology. The case involves assets sold in 2010, and ANI Pharmaceuticals is seeking to recover their value and secure a 5% …

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

ANI Pharmaceuticals (ANIP) announced its intent to appeal rulings in the CG Oncology matter to the Delaware Supreme Court after a trial court denied its motions for a new trial and judgment. The company aims to recover the value of assets sold to CG …

ANI Pharmaceuticals to Appeal Delaware Ruling Denying Post-Trial Motions in CG Oncology Asset Dispute

ANI Pharmaceuticals announced its intent to appeal a Delaware trial court's decision denying its post-trial motions concerning an unjust enrichment case linked to assets sold to CG Oncology in 2010. The company seeks to recover value, including a 5% royalty on future sales of …

Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks

ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance